If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year? My view is that only one of them looks attractive, while the other isn't worth the trouble. Here's why.The biotech stock to ...

Group 1 - Novavax, Inc. will participate in several upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners 2025 Global Healthcare Conference [1][2] - The TD Cowen conference will feature a fireside chat on March 4, 2025, while the Leerink Partners conference will include a presentation on the same date [1] - A webcast of the events will be available on the company's website, with replays accessible for 30 days post-conference [2] Group 2 - Novavax focuses on addressing significant health challenges through its expertise in vaccines and advanced technology platforms, including a protein-based nanoparticle and Matrix-M™ adjuvant [3] - The company's growth strategy emphasizes forming new partnerships by out-licensing its technology and vaccine assets early in the development process [3] - Novavax aims to expand its early-stage pipeline, starting with infectious diseases and potentially branching into other areas [3]

Novavax (NVAX) incurred a fourth-quarter 2024 loss of 51 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. In the year-ago quarter, the company reported a loss of $1.44 per share.Revenues in the quarter amounted to $88.3 million, which beat the Zacks Consensus Estimate of $86 million. However, the top line declined 70% on a year-over-year basis.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to date, Novavax stock has declined 9% against the industry ...

Novavax, Inc. (NASDAQ:NVAX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Particip ...

On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate.Also Read: Wegovy Maker Novo Nordisk To Buy Novavax’s Czech Republic Manufacturing Facility For $200 Million“In 2024, we unveiled our new corporate ...

Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.87 per share when it actually produced a loss of $0.76, delivering a surprise of 12.64%.Over the last four quarters, the company has surpassed con ...

Fourth Quarter 2024 Financial Results and Operational Highlights February 27, 2025 © 2025 NOVAVAX. All rights reserved. NovavaxTM (and all associated logos) is a trademark of Novavax, Inc. Matrix-MTM is a trademark of Novavax AB. 2 © 2025 NOVAVAX. All rights reserved. Non-GAAP Financial Measures The Company has used a non-GAAP financial measure in this presentation, which is Adjusted Licensing, Royalties and Other Revenue. Non-GAAP financial measures refer to financial information adjusted from financial me ...

COVID-19 Vaccine Developments - Novavax achieved approximately 70% market share in a regional retailer for its COVID-19 vaccine during the 2024-2025 season[26] - The company reported a $50 million milestone from Sanofi related to a COVID-19 pediatric trial[21] - Novavax's COVID-19 vaccine induces broad neutralizing responses across all tested variants, indicating acceptable coverage against currently circulating variants[26] - The partnership with Sanofi includes a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide[24] - Novavax's COVID-19 vaccine was launched in multiple markets, with a focus on driving value through R&D and diversified partnerships[16] - Novavax's late-stage pipeline includes a Phase 3 trial for a combination influenza and COVID-19 vaccine initiated in December 2024, with an initial cohort of approximately 2,000 participants[32][36] - The U.S. COVID-19 BLA PDUF is expected to be a significant focus in the near future[75] Financial Performance and Projections - Novavax's preliminary financial data for the year ended December 31, 2024, is still being finalized and may differ materially from actual results[7] - Novavax anticipates combined R&D and SG&A expenses of $700 million to $750 million for FY 2024, with a portion expected to be reimbursed by Sanofi[66] - Full year 2024 product sales guidance includes approximately $100 million in APA dose deliveries in 1H 2024 and $125 million in commercial market sales in 2H 2024[70] - Full year 2024 licensing, royalties, and other revenue guidance includes $450 million from the Sanofi agreement upfront payment and $25 million in royalty and other revenue from partner-related activities[70] - Current liabilities have decreased by over $1.3 billion since the end of 2022, including a settlement with Gavi[71] - The sale of the CZ manufacturing facility to Novo Nordisk generated $200 million in non-dilutive capital and annual cost reductions of approximately $80 million[71] Partnerships and Collaborations - The Sanofi partnership is expected to create multiple revenue streams and enhance access to Novavax's technology[24] - Sanofi partnership includes a $500 million upfront payment received in Q2 2024, with additional milestone payments totaling $700 million expected through 2026[28] - The company expects to receive ~$450 million in reimbursements from Sanofi for FY 2025, net of expected expenses[68] - The company is pursuing partnerships for its differentiated combination influenza vaccine candidates targeting older adults[37] - The company reported a significant interest in partnering or out-licensing its Matrix-M adjuvant technology[30] Research and Development - The company is focused on a lean operating model to drive shareholder value and has a diversified vaccine pipeline including COVID-19 and influenza candidates[12] - Novavax's technology platform is based on a recombinant protein-based nanoparticle, which is clinically proven and adaptable for combination vaccines[14] - Novavax's Matrix-M™ adjuvant shows promise in enhancing immune responses and is being explored for use in new vaccine formulations[46][47] - Novavax's H5N1 avian pandemic influenza vaccine candidate is currently undergoing preclinical evaluation, with the ability to pivot to new strains as they emerge[42] - The company anticipates advancements in its early-stage pipeline and enhanced partnerships in the coming years[75] Milestones and Future Outlook - Key milestones for 2025 include additional Sanofi-related milestones and data from late-stage assets[75] - Data from the initial cohort in the influenza Phase 3 trial is anticipated in 2025[76]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) Delaware 22-2816046 (State of incorporation) (I.R.S. ...